Latest Papillary thyroid cancer Stories
DALLAS, April 6, 2015 /PRNewswire/ -- MarketReportsOnline.com adds US Thyroid Cancer Market: Trends and Opportunities (2015 - 2019) industry research report of 75 pages
- Data Presented This Week at ENDO 2015 Annual Meeting - SOUTH SAN FRANCISCO, Calif., March 6, 2015 /PRNewswire/ -- Veracyte,
SOUTH SAN FRANCISCO, Calif., Feb.
Thyroid cancer increased from 14th to 5th most common cancer in women over last 20 years Fremont, California (PRWEB) May 19, 2014 The dramatic increase
WOODCLIFF LAKE, N.J., Feb. 2, 2014 /PRNewswire/ -- Eisai Inc. announced today that the Phase 3 SELECT trial (Study 303) of investigational agent lenvatinib met its primary endpoint.
Researchers at the National Institutes of Health (NIH), Bethesda, MD, have taken the first steps to determine if a protein, called Programmed Death Ligand 1 (PD-L1), can help to predict which thyroid cancer patients will most likely have a recurrence of the disease.
For many years, patients with advanced thyroid cancer faced bleak prospects and no viable treatment options.
Presence of the genetic mutation BRAF V600E was significantly associated with increased cancer-related death among patients with papillary thyroid cancer (PTC); however, because overall mortality in PTC is low and the association was not independent of tumor characteristics, how to use this information to manage mortality risk in patients with PTC is unclear.